ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
239.07
+0.88 (0.37%)
Nov 17, 2026, 3:45 PM EST - Market open
ResMed Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, ResMed stock has a consensus rating of "Buy" and an average price target of $264.33. The average 1-year stock price forecast is 10.57% higher than the current stock price, while the lowest is $210 (-12.16%) and the highest is $320 (+33.85%).
Price Target: $264.33 (+10.57%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ResMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 8 | 10 | 11 | 10 | 10 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 18 | 20 | 20 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $320 | Buy | Reiterates | $320 | +33.85% | Nov 2, 2026 |
| Citi | Citi | Hold Maintains $240 → $270 | Hold | Maintains | $240 → $270 | +12.94% | Nov 2, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $233 | Hold | Maintains | $233 | -2.54% | Oct 30, 2026 |
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Oct 30, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $225 → $260 | Hold | Maintains | $225 → $260 | +8.75% | Oct 30, 2026 |
Financial Forecast
Revenue This Year
5.83B
from 5.65B
Increased by 3.12%
Revenue Next Year
6.21B
from 5.83B
Increased by 6.43%
EPS This Year
12.14
from 11.17
Increased by 8.69%
EPS Next Year
13.23
from 12.14
Increased by 8.94%
EPS and Forward PE are based on non-GAAP adjusted numbers.